Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference
07 Maggio 2024 - 1:00PM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for virology and immunology indications, today announced that Jay
R. Luly, Ph.D., President and Chief Executive Officer, and Tara L.
Kieffer, Ph.D., Chief Product Strategy Officer, will participate in
a fireside chat at the JMP Securities Life Sciences Conference on
May 14, 2024 at 10:00 a.m. ET in New York, NY.
A live webcast of the event will be accessible by visiting the
“Events and Presentations” section on the “Investors” page of
Enanta’s website at www.enanta.com. A replay of the webcast will be
available following the presentation and will be archived for at
least 30 days.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for virology and immunology
indications. Enanta’s research and development programs are
currently focused on respiratory syncytial virus (RSV) and chronic
spontaneous urticaria (CSU) and the company has previously advanced
clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic
hepatitis B virus (HBV) infection.
Glecaprevir, a protease inhibitor discovered by Enanta, is part
of one of the leading treatment regimens for curing chronic
hepatitis C virus infection (HCV) and is sold by AbbVie in numerous
countries under the trade names MAVYRET®(U.S.) and
MAVIRET®(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s
royalties from HCV products developed under its collaboration with
AbbVie contribute ongoing funding to Enanta’s operations. Please
visit http://www.enanta.com for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240507114970/en/
Media and Investors Contact: Jennifer Viera
jviera@enanta.com
Grafico Azioni Enanta Pharmaceuticals (NASDAQ:ENTA)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Enanta Pharmaceuticals (NASDAQ:ENTA)
Storico
Da Nov 2023 a Nov 2024
